Polish Stem Cells Bank S.A.   Report issue

For profit Phase 2
Founded: Warsaw Poland (2002)
Status: No NME R&D (2002)

Organization Overview

First Clinical Trial
2018
NCT03887208
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2018

Timeline

NOW
  • Now

Alternative names

Polish Stem Cells Bank S.A.

Active Ingredients

Drugs in Phase 2 Trials (1)

autologous adipose-derived mesenchymal stem cells (2 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cicatrix (Phase 2)

Cutis Laxa (Phase 2)

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 1